本帖最后由 老马 于 2012-1-13 21:20 编辑 5 `" A8 G0 S- X. E7 V4 ~
# h7 l0 c5 q, H3 q. H
爱必妥和阿瓦斯丁的比较1 |; |" m2 t% I! A* L) V
7 W* ]6 B% ~4 T
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
: G, ~" J# K' Z, l' B
' x: N" s9 B$ G0 h" E( a8 O
) a6 Y0 s4 Y" T! b# K* v: u( `& phttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 M! W% i" N3 ]0 c& g$ D" X==================================================! z2 i, X8 F% I: X
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL); o- Q/ t+ K9 L3 @; O6 {
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 L( ]) P- O$ cResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported." p6 r; r% D( I( R
|